<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01608971</url>
  </required_header>
  <id_info>
    <org_study_id>007</org_study_id>
    <nct_id>NCT01608971</nct_id>
  </id_info>
  <brief_title>Protamine in Cardiac Surgery and Haemostasis</brief_title>
  <acronym>PROTT</acronym>
  <official_title>The Effects of Heparin Level Based Versus Weight Based Protamine Dosing on Protamine Demand, Markers of Haemostasis, Blood Product Utilization and Perioperative Blood Loss in Patients Undergoing Extended Cardiac Surgery Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heart and Diabetes Center North-Rhine Westfalia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heart and Diabetes Center North-Rhine Westfalia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protamine is used after Cardiopulmonary Bypass (CPB) to reverse the anticoagulant effects of
      heparin and restore coagulation. Convincing evidence from in-vitro and in-vivo studies
      suggest that an overdose of protamine has anticoagulant effects which might lead to bleeding
      complications. Heparin levels usually decrease during cardiac surgery with CPB. Therefore, a
      protamine regimen based on the initial heparin dose before CPB might lead to overdose of
      protamine. In contrast, a protamine regimen based on the actual heparin concentration may
      avoid this condition. The investigators compare both regimens of protamine dosing in patients
      undergoing complex surgery with CPB and assess its effect on the amount of protamine given,
      markers of the coagulation system, utilization of blood products and perioperative blood
      loss.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before induction of anesthesia, patients are randomized to the two different dosing regimen
      for protamine. Both, the anesthetist and the surgeon were blinded regarding the grouping of
      the patients.

      Anesthesia and CPB

      Anesthesia is performed as a balanced anesthesia with a bolus of fentanyl, etomidate,
      pancuronium-bromide followed by a continuous infusion of remifentanil and vaporization of
      sevoflurane. Additionally, in all patients a continuous infusion of 0.25 µg/kg/min milrinone
      will be started after induction of anesthesia. Further inotropic or vasoactive agents
      (Dobutamine 3-5 µg/kg/min; epinephrine 0.05-0.2 µg(kg/min, norepinephrine 0.05-0.2 µg/kg/min)
      will be only given when a target cardiac index of &lt; 2.2 l/m² BSA and mean arterial pressure
      of &gt;70 mmHg is not achieved with this therapy.

      In order to compensate the degree of hemodilution due to differences in weight, in patients
      with a body surface area (BSA) of &lt;1.8 m², a CPB system with a priming volume of 1100 ml will
      be used while in patients with a BSA of &gt;1.8m² a system with a priming volume of 1500 ml was
      employed. CBP will be performed with open non-coated CPB circuits in mild hypothermia with a
      core temperature of 32-34°C. Cardioplegia will be achieved using warm blood cardioplegia
      according to Calafiore.

      All patients receive tranexamic acid (TA) with a bolus of 1 g to the patient, 0.5 g added to
      the CPB volume and a continuous infusion of 0.2 g/hour during CPB.

      Heparin and Protamine Management

      Heparin will be given with a bolus of 400 IU/kg to achieve a target celite ACT (Actalyke ACT,
      Helena Lab. Beaumont, TX USA) value of &gt;450 seconds. If this target is not reached,
      additional boluses of 1/3 rd of the first dose will be given until prolongation to the target
      value is achieved. Additional 10.000 units of heparin will be given into the priming volume
      of the CPB circuit.

      Heparin concentrations were measured five minutes after beginning of CPB using the white
      (range 3.4-6.8 IU/ml heparin) heparin protamine titration (HPT) cartridge of the Hepcon HMS
      Plus™ device (Medtronic INC, Minneapolis, Min, USA) and shortly after termination of CPB
      using the golden HPT cartridge (range 2.0 - 5.4 IU/ml heparin).

      The total protamine dose consists of 100 ml. Of this 80 ml will be given as a short infusion
      over 10 min. directly after termination of CPB. The remaining 20 ml will be given when the
      residual CPB blood is re-infused into the patient after arterial decannulation, which will be
      performed 10-15 minutes after weaning from CPB.

      In the weight based protamine group (Group 1, the total amount of protamine will be
      calculated 1:1 according to the initial heparin dose necessary to achieve the target ACT of
      &gt;450 sec. In the heparin level based group, the total protamine amount will be calculated 1:1
      according to the actual heparin level measured after termination of CPB with the use of
      Hepcon HMS Plus™ device.

      Coagulation Tests

      Fifteen minutes after infusion of protamine, the INTEM, FIBTEM and HEPTEM test will be
      performed on the ROTEM thromboelastometry system (TEM International GmbH, Munich Germany). In
      all tests, the coagulation time (CT) reflects the period until clot formation starts; the
      clot formation time (CFT) reflects the period until a clot strength of 20 mm is achieved and
      the maximal clot firmness MCF)reflects the maximal clot strength. In the INTEM test the
      intrinsic coagulation pathway is activated.

      Transfusion triggers

      During CPB the critical hemoglobin (Hb) triggering transfusion of packed red blood cells
      (PRBC) is defined at 8 g/dl. After CPB, in patients with a CI &gt;2.2 l/m² the critical value is
      at &gt;8-9 g/dl, while in patients needing further medical support with dobutamine/epinephrine
      or norepinephrine the minimum target was defined at &gt;9-10 g/dl.

      In patients with diffuse bleeding after protamine administration, therapy with fresh frozen
      plasma (FFP), prothrombin complex concentrate (Beriplex, CSL Behring, Marburg, Ger) ,
      fibrinogen concentrate (Haemocomplettan P®, CSL Behring, Marburg, Germany) and single donor
      aphaeresis platelet concentrates will be based on the results of the ROTEM analysis. However,
      these blood products will only be given when diffuse microvascular bleeding is observed in
      the operation field.

      In case of a moderate prolongation of the CT (240-360 sec) in the INTEM test (and comparable
      result in the HEPTEM test) 3-4 units of FFP will be transfused. If bleeding persists,
      additional 3-4 units of FFP or in case of a prolongation of the CT&gt;360 sec. 2000-4000 IU of
      prothrombin complex concentrate will be given.In case of an MCF &lt; 45 mm to platelet
      concentrates will be transfused.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>INTEM HEPTEM and FIBTEM Test of the ROTEM Coagulation Analyzer</measure>
    <time_frame>Tests will be measured 15 minutes after Protamine infusion</time_frame>
    <description>The Intem test of the ROTEM analyzer evaluates the response of the heamostatic system to activation of the intrinsic coagulation system. The following parameters of the INTEM test will be analyzed. CT [seconds](coagulation time), CFT [seconds] (clot formation time) and the CT [seconds] of the HEPTEM test which is non sensitive for residual heparine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rotem MCF Fibtem and MCF Intem</measure>
    <time_frame>15 Minutes after protamine infusion</time_frame>
    <description>The following parameters of the INTEM test will be analyzed: MCF [mm] (maximum clot firmness) which correlates with the platelet count. Furthermore, the MCF [mm] of the FIBTEM test will be analyzed, which correlates with the fibrinogen concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transfusion of Blood Products and Coagulation Factors</measure>
    <time_frame>From protamine administration until 12 h after surgery</time_frame>
    <description>The transfusion of blood products and coagulation factors will be assesed from protamine administration until 12 hours postoperatively .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 h Postoperative Blood Loss</measure>
    <time_frame>15 min after protamine administration until 12 hours postoperatively</time_frame>
    <description>The intra and postoperative blood loss from the time point of protamine administration until 12 hours postoperatively will be analyzed.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Bleeding</condition>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Weight based protamine group</arm_group_label>
    <description>In this group the dose of protamine is calculated by the weight of the patients (400 IU/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin level based protamine group</arm_group_label>
    <description>In this group the protamine dose will be calculated 1:1 according to the heparin level measured after termination of cardiopulmonary bypass.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing complex cardiac surgery using cardiopulmonary bypass with mitral valve
        repair/replacement and 2-4 coronary artery bypass grafting including the left thoracic
        artery
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary surgery

          -  Preoperative hemoglobin value &lt; 12 g/l

          -  Preoperative platelet count &lt; 200 c/µl

          -  Patients with a body weight &lt; 50 kg

          -  No known defect of the coagulation system

          -  Normal pre-operative ROTEM values of the INTEM and FIBTEM

          -  Patients with unimpaired renal function (creatinine clearance &lt; 30 ml/kg/min)

        Exclusion Criteria:

          -  &lt;18 years

          -  No informed consent

          -  Re-do surgery

          -  Known defect of the coagulation system

          -  Renal impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Koster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart &amp; Diabetes Center NRW, Ruhr University Bochum, 32545 Bad Oeynhausen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart &amp; Diabetes Center NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>North Rhine-Westphalia</state>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Koster A, Börgermann J, Gummert J, Rudloff M, Zittermann A, Schirmer U. Protamine overdose and its impact on coagulation, bleeding, and transfusions after cardiopulmonary bypass: results of a randomized double-blind controlled pilot study. Clin Appl Thromb Hemost. 2014 Apr;20(3):290-5. doi: 10.1177/1076029613484085. Epub 2013 Apr 4.</citation>
    <PMID>23564056</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2012</study_first_submitted>
  <study_first_submitted_qc>May 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2012</study_first_posted>
  <results_first_submitted>March 17, 2015</results_first_submitted>
  <results_first_submitted_qc>November 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2015</results_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heart and Diabetes Center North-Rhine Westfalia</investigator_affiliation>
    <investigator_full_name>Andreas Koster</investigator_full_name>
    <investigator_title>Senior anaestetist</investigator_title>
  </responsible_party>
  <keyword>Protamine</keyword>
  <keyword>heparin level</keyword>
  <keyword>haemostasis</keyword>
  <keyword>thromboelastometry</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>Patients undergoing cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Hemostatics</mesh_term>
    <mesh_term>Protamines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Heparin Level Based Protamine Group</title>
          <description>In this group the protamine dose will be calculated 1:1 according to the heparin level measured after termination of cardiopulmonary bypass.</description>
        </group>
        <group group_id="P2">
          <title>Weight Based Protamine Group</title>
          <description>In this group the dose of protamine is calculated by the weight of the patients (400 IU/kg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Weight Based Protamine Group</title>
          <description>In this group the dose of protamine is calculated by the weight of the patients (400 IU/kg)</description>
        </group>
        <group group_id="B2">
          <title>Heparin Level Based Protamine Group</title>
          <description>In this group the protamine dose will be calculated 1:1 according to the heparin level measured after termination of cardiopulmonary bypass.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>INTEM HEPTEM and FIBTEM Test of the ROTEM Coagulation Analyzer</title>
        <description>The Intem test of the ROTEM analyzer evaluates the response of the heamostatic system to activation of the intrinsic coagulation system. The following parameters of the INTEM test will be analyzed. CT [seconds](coagulation time), CFT [seconds] (clot formation time) and the CT [seconds] of the HEPTEM test which is non sensitive for residual heparine.</description>
        <time_frame>Tests will be measured 15 minutes after Protamine infusion</time_frame>
        <population>Rotem INTEM CT, CFT, MCF and FIBTEM MCF and Heptem CT</population>
        <group_list>
          <group group_id="O1">
            <title>Heparin Level Based Protamine Group</title>
            <description>In this group the protamine dose will be calculated 1:1 according to the heparin level measured after termination of cardiopulmonary bypass.</description>
          </group>
          <group group_id="O2">
            <title>Weight Based Protamine Group</title>
            <description>In this group the dose of protamine is calculated by the weight of the patients (400 IU/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>INTEM HEPTEM and FIBTEM Test of the ROTEM Coagulation Analyzer</title>
          <description>The Intem test of the ROTEM analyzer evaluates the response of the heamostatic system to activation of the intrinsic coagulation system. The following parameters of the INTEM test will be analyzed. CT [seconds](coagulation time), CFT [seconds] (clot formation time) and the CT [seconds] of the HEPTEM test which is non sensitive for residual heparine.</description>
          <population>Rotem INTEM CT, CFT, MCF and FIBTEM MCF and Heptem CT</population>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CFT Intem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="78" upper_limit="131"/>
                    <measurement group_id="O2" value="117" lower_limit="103" upper_limit="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CT Intem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178" lower_limit="163" upper_limit="199"/>
                    <measurement group_id="O2" value="253" lower_limit="202" upper_limit="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CT Heptem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185" lower_limit="169" upper_limit="201"/>
                    <measurement group_id="O2" value="267" lower_limit="209" upper_limit="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transfusion of Blood Products and Coagulation Factors</title>
        <description>The transfusion of blood products and coagulation factors will be assesed from protamine administration until 12 hours postoperatively .</description>
        <time_frame>From protamine administration until 12 h after surgery</time_frame>
        <population>Transfusion of RBC</population>
        <group_list>
          <group group_id="O1">
            <title>Weight Based Protamine Group</title>
            <description>In this group the dose of protamine is calculated by the weight of the patients (400 IU/kg)</description>
          </group>
          <group group_id="O2">
            <title>Heparin Level Based Protamine Group</title>
            <description>In this group the protamine dose will be calculated 1:1 according to the heparin level measured after termination of cardiopulmonary bypass.</description>
          </group>
        </group_list>
        <measure>
          <title>Transfusion of Blood Products and Coagulation Factors</title>
          <description>The transfusion of blood products and coagulation factors will be assesed from protamine administration until 12 hours postoperatively .</description>
          <population>Transfusion of RBC</population>
          <units>percentage of patients transfused</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RBC transfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCC transfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FFP transfusiom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RDPC transfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrinogen transfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12 h Postoperative Blood Loss</title>
        <description>The intra and postoperative blood loss from the time point of protamine administration until 12 hours postoperatively will be analyzed.</description>
        <time_frame>15 min after protamine administration until 12 hours postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Weight Based Protamine Group</title>
            <description>In this group the dose of protamine is calculated by the weight of the patients (400 IU/kg)</description>
          </group>
          <group group_id="O2">
            <title>Heparin Level Based Protamine Group</title>
            <description>In this group the protamine dose will be calculated 1:1 according to the heparin level measured after termination of cardiopulmonary bypass.</description>
          </group>
        </group_list>
        <measure>
          <title>12 h Postoperative Blood Loss</title>
          <description>The intra and postoperative blood loss from the time point of protamine administration until 12 hours postoperatively will be analyzed.</description>
          <units>ml/12 hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="620" lower_limit="600" upper_limit="700"/>
                    <measurement group_id="O2" value="723" lower_limit="600" upper_limit="850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rotem MCF Fibtem and MCF Intem</title>
        <description>The following parameters of the INTEM test will be analyzed: MCF [mm] (maximum clot firmness) which correlates with the platelet count. Furthermore, the MCF [mm] of the FIBTEM test will be analyzed, which correlates with the fibrinogen concentration.</description>
        <time_frame>15 Minutes after protamine infusion</time_frame>
        <population>Patients of both groups</population>
        <group_list>
          <group group_id="O1">
            <title>Heparin Level Based Protamine Group</title>
            <description>In this group the protamine dose will be calculated 1:1 according to the heparin level measured after termination of cardiopulmonary bypass.</description>
          </group>
          <group group_id="O2">
            <title>Weight Based Protamine Group</title>
            <description>In this group the dose of protamine is calculated by the weight of the patients (400 IU/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Rotem MCF Fibtem and MCF Intem</title>
          <description>The following parameters of the INTEM test will be analyzed: MCF [mm] (maximum clot firmness) which correlates with the platelet count. Furthermore, the MCF [mm] of the FIBTEM test will be analyzed, which correlates with the fibrinogen concentration.</description>
          <population>Patients of both groups</population>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCF Intem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="51" upper_limit="60"/>
                    <measurement group_id="O2" value="57" lower_limit="53" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCF Fibtem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="7" upper_limit="14"/>
                    <measurement group_id="O2" value="13" lower_limit="10" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Heparin Level Based Protamine Group</title>
          <description>In this group the protamine dose will be calculated 1:1 according to the heparin level measured after termination of cardiopulmonary bypass.</description>
        </group>
        <group group_id="E2">
          <title>Weight Based Protamine Group</title>
          <description>In this group the dose of protamine is calculated by the weight of the patients (400 IU/kg)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Excessive bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>small study cohort</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Andreas Koster</name_or_title>
      <organization>Heart and Diabetes Center NRW</organization>
      <phone>0043 5731 3284</phone>
      <email>akoster@hdz-nrw.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

